Role of Prostate Specific Antijen in Prostatic Adenocarcinoma Detection in Patients With Benign Prostate Hyperplasia and Were Placed Urethral Catheter After Acute Urinary Retention

Objective: Acute urinary retention (AUR) is one of the most important complications in be-nign prostate hyperplasia (BPH) patients and its treatment is generally urethral catheterization in acute period. Studies are showing that AUR and urethral catheter placement may cause an increase in serum PSA levels. Our objective in this study was to investigate the relationship between in-creased PSA levels and prostate cancer (PCa) inci-dence in the patient group after AUR and urethral catheter placement. Material and Methods: Seventy-seven pa-tients who had an indwelling urethral catheter due to AUR, performed prostate biopsy due to high PSA levels and then surgical treatment for clinic BPH were retrospectively examined. Age, pros-tate volumes, pre-biopsy total serum PSA and PSA densities were noted. Total serum PSA rates, PSA densities and prostate volumes were compared for the groups that PCa was detected (n=6) and not detected (n=71) according to biopsy or surgical specimen results. Results: Mean age of the patients was 65.2±3.9 years. Mean prostate volume was mea-sured as 64.1±12.8 g, mean serum total PSA level as 9.2±4.2 ng/mL and mean serum PSA density as 0.15±0.08 mg/mL/g. In PSA groups with a serum total PSA level of ≤4.0, 4-10, 10-20 and >20, PCa prevalence rates were detected 0%, 4.3%, 13.4% and 20%, respectively. Total PSA levels and PSA densities were found statistically higher in PCa detected group. Conclusions: PCa incidence is low in patients who were placed urethral catheter after AUR. For these patients prostate biopsy should be per-formed only in chosen cases.

Prostat Spesifik Antijenin Akut Üriner Retansiyon Sonrası Üretral Kateter Yerleştirilen ve Benign Prostat Hiperplazisi Olan Hastalarda Prostat Adenokarsinomu Saptamadaki Rolü

Amaç: Akut idrar retansiyonu (AİR) benign prostat hiperplazisi (BPH) hastalarında en önemli komplikasyonlardan biridir ve tedavisi genellikle akut dönemde üretral kateterizasyondur. AİR ve üretral kateter yerleştirilmesinin serum PSA sevi-yelerinde bir artışa neden olabileceğini gösteren çalışmalar vardır. Bu çalışmada amacımız, AİR sonrası üretral kateter yerleştirilen hasta grubun-da artmış PSA düzeyleri ile prostat kanseri (PCa) insidansı arasındaki ilişkiyi araştırmaktır. Gereç ve Yöntemler: AUR nedeniyle kalıcı bir üretral kateteri olan 77 hastada, yüksek PSA seviyeleri nedeniyle yapılan prostat biyopsileri ve daha sonra klinik BPH için yapılan cerrahi teda-viler retrospektif olarak incelendi. Hastaların yaş, prostat hacimleri, biyopsi öncesi total serum PSA ve PSA dansiteleri kaydedildi. Biyopsi veya cerra-hi örnek sonuçlarına göre total PSA oranları, PSA dansiteleri ve prostat hacimleri PCa’nın saptandığı (n = 6) ve saptanmadığı (n = 71) gruplar için kar-şılaştırıldı. Bulgular: Hastaların yaş ortalaması 65.2 ± 3.9 idi. Ortalama prostat hacmi 64.1 ± 12.8 g, or-talama serum total PSA seviyesi 9.2 ± 4.2 ng / mL ve ortalama serum PSA dansitesi 0.15 ± 0.08 mg / mL / g olarak ölçülmüştür. Serum total PSA düze-yi ≤4.0, 4-10, 10-20 ve >20 olan PSA gruplarında PCa prevalansı sırasıyla % 0, % 4,3, % 13,4 ve % 20 olarak tespit edildi. Toplam PSA düzeyleri ve PSA dansiteleri, PCa tespit edilen grupta istatistiksel olarak daha yüksek bulundu. Sonuç: AİR sonrası üretral kateter yerleştiri-len hastalarda PCa insidansı düşüktür. Bu hastalar için prostat biyopsisi sadece seçilmiş vakalarda yapılmalıdır.

Kaynakça

1. Bushman W. Etiology, epidemiology, and natural histo-ry of benign prostatic hyperplasia. Urol Clin North Am 2009;36:403–15.

2. Bosch JL, Hop WC, Kirkels WJ, Schröder FH. The inter-national prostate symptom score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate, and residual urine volume. Br J Urol 1995;75:622–630.

3. Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Asso-ciation of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide co-hort study of 3,009,258 men. Eur Urol 2011;60:691-8.

4. Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is there evidence of a relationship between benign prostat-ic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009;55:864–873 . 5. Schenk JM, Kristal AR, Arnold KB, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol 2011;173:1419–1428.

6. Simons BD, Morrison AS, Young RH, Verhoek-Oftedahl W. The relation of surgery for prostatic hypertrophy to car-cinoma of the prostate. Am J Epidemiol 1999;138:294–300.

7. Kefi A, Koseoglu H, Celebi I, Yorukoglu K, Esen A. Rela-tion between acute urinary retention, chronic prostatic in-flammation, and accompanying elevated prostate-specific antigen. Scand J Urol Nephrol 2006;40:155–60.

8. Shadi Al-Khalil, Christine Ibilibor, James Thomas Cam-mack, Werner de Riese. Association of prostate volume with incidence and aggressiveness of prostate cancer. Res Rep Urol 2016;8:201-205.

9. Kravchick S, Bunkin I, Peled R, et al. Patients with elevat-ed serum PSA and indwelling catheter after acute urinary retention: prospective study of 63 patients with 7-year fol-low-up. J Endourol 2007;21:1203-6.

10. Antunes AA, Barbosa JA, Reis ST, et al. Prostate biopsy in patients with long-term use of indwelling bladder catheter: What is the rationale? Urol Oncol 2012;30:620-3.

11. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection, and monitoring. Nat Rev Cancer 2008;8:268–78.

12. Pienta KJ. Critical appraisal of prostate-specific anti-gen in prostate cancer screening: 20 years later. Urology 2009;73:11–20.

13. Parekh N, Lin Y, Marcella S, Kant AK, Lu-Yao G. Associa-tions of lifestyle and physiologic factors with prostate-spe-cific antigen concentrations: Evidence from the National Health and Nutrition Examination Survey (2001–2004). Cancer Epidemiol Biomarkers Prev 2008;17:2467–72.

14. McNeill SA, Hargreave TB. Efficacy of PSA in the detection of carcinoma of the prostate in patients presenting with acute urinary retention. R Coll Surg Edinb 2000;45:227–30.

15. Feero P, Nickel JC, Brawn P, Young I. Prostatic infarction associated with aortic and iliac aneurism repair. J Urol 1990;143:367–8.

16. Batislam E, Arik AI, Karakoc A, Uygur MC, Germiyano-glu RC, Erol D. Effect of transurethral indwelling catheter serum prostate- specific antigen level in benign prostatic hyperplasia. Urology 1997;49:50–4.

17. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156–61.

18. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessel-la RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-5.

19. Pinsky PF, Kramer BS, Crawford ED, et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 2006;68:352-6.

20. Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate vol-ume in the management of patients with symptomatic be-nign prostatic hyperplasia. Eur Urol 2003;44:695-700. 21. Putra IB, Hamid AR, Mochtar CA, Umbas R. Relation-ship of age, prostate-specific antigen,and prostate vol-ume in Indonesian men with benign prostatic hyperplasia. Prostate Int 2016;4:43-8.

22. Agnihotri S, Mittal RD, Kapoor R, Mandhani A. Asymp-tomatic prostatic inflammation in men with clinical BPH and erectile dysfunction affects the positive predictive value of the prostate-specific antigen. Urol Oncol 2014;32:946-51.

23. Yli-Hemminki TH, Laurila M, Auvinen A, et al. Histolog-ical inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int 2013;112:735-41.

Kaynak Göster

Yeni Üroloji Dergisi
  • ISSN: 1305-2489
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2005

843173

Sayıdaki Diğer Makaleler

Percutaneous Nephrolithotomy is not Frightening in Elderly Patients: A Single Center Outcomes

Yavuz Tarık ATIK, Hacı İ. ÇİMEN, Deniz GÜL, Safa ARSLAN, Fikret HALİS

Effect Of Metabolic Syndrome-Related Parameters On Overactive Bladder

Arif AYDIN, Mahmut Sami TUZCU, Adeviye ELÇİ ATILGAN, Mehmet Giray SÖNMEZ, Serkan ÖZCAN, Yunus Emre GÖGER, Mehmet BALASAR

Transüretral Rezeksiyon Sonrası Kas İnvaze Mesane Tümörlerinin Klinik Evrelemesinde, Tanısal Doğruluğu Artırabilecek Ek Parametreler

İsmail SELVİ, Halil BAŞAR

Current Diagnosis, Treatment And Follow-up Procedures of Paratesticular Masses

Mustafa Gürkan YENİCE, Ramazan UĞUR, İsmail YİĞİTBAŞI, Kamil Gökhan ŞEKER, Halil BAYTEKİN, Yavuz Onur DANACIOĞLU, Selçuk ŞAHİN, Ali İhsan TAŞÇI

The Effectiveness of Topical Steroid Cream in the Management of Phimosis Developed Following Circumcision Performed With Thermocautery

Osman AKYÜZ, Mehmet Nuri BODAKÇI, Zeynep TATAR, Müslüm ERGÜN, Soner ÇOBAN, Haydar Kamil ÇAM

Retrograd İntrarenal Cerrahi Esnasında Oluşan Vücut Sıcaklık Değişikliklerini Etkileyen Faktörler

Vahit GÜZELBURÇ, MuSTAFA SOYTAŞ, Murat Can KİREMİT, Bülent ERKURT, Bülent ALTAY, Kamil DARÇIN, Ziya AKBULUT, Selami ALBAYRAK

Edoxaban-related Spontaneous Renal Hematoma: A Case Report

yberk İPLİKÇİ, Özgür EFİLOĞLU, Asıf YILDIRIM

18 Yaşından Küçük Pediatrik Hastalarda Uygulanan Farklı Perkütan Nefrolitotomi Prosedürlerinin Değerlendirilmesi

Cem ALAN, Onur DEDE

Çocukluk Döneminde İşeme Bozukluğu Görülen Erişkinlerde Aşırı Aktif Mesane Ortaya Çıkmasını Kolaylaştıran Faktörler

Okan ALKIŞ, Aykut BAŞER, Yusuf ÖZLÜLERDEN, Ali Ersin ZÜMRÜTBAŞ, Zafer AYBEK, Taha ÖLÇÜCÜ

İleri Yaş Kas İnvaziv Olmayan Mesane Kanserli Hastalarda Rekürens ve Progresyon Gelişimine Etkilidir

Göksel BAYAR, Muhammet Fatih KILINÇ